JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

High-Throughput Antigen Microarray Identifies Longitudinal Prognostic Autoantibody for Chemoimmunotherapy in Advanced Non-Small Cell Lung Cancer

  • 0Department of Clinical Laboratory, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China.
Molecular & Cellular Proteomics : Mcp +

|

March 21, 2024

|

March 21, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

Researchers identified predictive autoantibodies (AAbs) for advanced non-small cell lung cancer (aNSCLC) patients undergoing chemoimmunotherapy. These biomarkers, including MAX and DHX29, correlate with treatment response and progression-free survival, offering new insights for personalized therapy.

Area Of Science

  • Oncology
  • Immunology
  • Biomarker Discovery

Background

  • Chemoimmunotherapy is standard for advanced non-small cell lung cancer (aNSCLC), but drug resistance limits efficacy.
  • There is a critical need for reliable biomarkers to predict treatment response and outcomes in aNSCLC patients.

Purpose Of The Study

  • To discover, verify, and validate longitudinal predictive autoantibodies (AAbs) for aNSCLC patients before and after chemoimmunotherapy.
  • To identify biomarkers that correlate with early treatment response and progression-free survival (PFS).

Main Methods

  • Utilized a three-phase strategy involving HuProt microarrays, aNSCLC-focused microarrays, and ELISA for AAb discovery and validation.
  • Analyzed 528 plasma samples from 267 aNSCLC patients and 30 FFPE samples.
  • Validated prognostic markers using immunohistochemistry and public immunotherapy datasets.

Main Results

  • Identified and validated MAX and DHX29 as pre-treatment biomarkers, and MAX and TAPBP as on-treatment predictive markers.
  • All identified AAbs positively correlated with early response and PFS (p < 0.05).
  • MAX AAb kinetics differed between responders and non-responders, and MAX protein/mRNA levels predicted PFS.

Conclusions

  • A panel of autoantibodies (MAX, DHX29, TAPBP) can serve as predictive biomarkers for chemoimmunotherapy in aNSCLC.
  • Longitudinal analysis of these AAbs provides insights into treatment response and patient outcomes.
  • MAX AAb kinetics and protein/mRNA levels are promising prognostic indicators for aNSCLC patients receiving immunotherapy.

Keywords: